Date: 2014-03-25
Type of information: Grant
Company: Adaptimmune (UK)
Investors: Biomedical Catalyst Fund (UK)
Amount: £2.1 million (€2.5 million)
Funding type: grant
Planned used: The funding award will be used to expedite Adaptimmune’s second clinical programme with a new TCR to enter the clinic in the UK. The award will support preclinical testing and regulatory approval for an initial pilot trial with a new TCR targeting an undisclosed protein found to be highly expressed in some forms of breast cancer and other cancer types. The trial is planned to start in 2015.
Others: * On March 25, 2014, Adaptimmune has announced that it has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK’s innovation agency the Technology Strategy Board and the Medical Research Council. Adaptimmune’s existing clinical programme targets a peptide from two cancer testis antigens (CT antigens) called NY-ESO-1 and LAGE-1. Both proteins are expressed in multiple cancers and the company is running studies in the US in multiple myeloma, melanoma, synovial sarcoma and ovarian cancer, with its most recent results reported for multiple myeloma at the annual conference of the American Society of Hematology in December 2013.
Therapeutic area: Cancer - Oncology
